| Adalimumab | Infliximab | Ustekinumab | |
|---|---|---|---|
| Lost to follow-up | 5% (1/20) | 23.5% (4/17) | 22% (2/9) |
| Continuing treatment | 40% (8/20) | 29.4% (5/17) | 67% (6/9) |
| Withdrawal/ Discontinuation by doctor | 5% (1/20) | 5.9% (1/17) | 11% (1/9) |
| Discontinuation due to good response | 20% (4/20) | – | – |
| Change of treatment | 30% (6/20) | 41.2% (7/17) | – |